Arteris posts FY 2025 ACV plus royalties of USD 83.6 million, up 28 percent

Reuters
02/13
Arteris posts FY 2025 ACV plus royalties of USD 83.6 million, up 28 percent

Arteris reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For Q4 2025, revenue figures were released, and for FY 2025, Arteris also provided revenue data. The company issued guidance for the first quarter (Q1) and full year (FY) 2026, projecting ACV plus royalties in the range of USD 85.0 million to USD 89.0 million for Q1 2026 and USD 100.0 million to USD 104.0 million for FY 2026. Revenue is expected to be between USD 20.5 million and USD 21.5 million for Q1 2026 and between USD 89.0 million and USD 93.0 million for FY 2026. During the reporting period, Arteris highlighted that Blaize deployed its FlexNoC IP for the Blaize AI platform, enabling a programmable, energy-efficient solution for edge and cloud-based AI. Additionally, Arteris became a founding member of the CHASSIS program, an initiative led by Bosch and including automotive OEMs such as BMW, Renault, and Stellantis, aimed at creating an open automotive chiplet platform. The company also noted that non-GAAP financial measures, including non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating loss, non-GAAP net loss, non-GAAP net loss per share, and free cash flow, were disclosed with reconciliations to the most comparable GAAP measures. The company’s management will host a conference call on February 12, 2026, to discuss these results and its financial outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arteris Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653991-en) on February 12, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10